AT-101 or placebo (P) with docetaxel (D) in second-line NSCLC with gene signature biomarker development

Authors
Category Primary study
JournalJournal of Clinical Oncology
Year 2009
This article has no abstract
Epistemonikos ID: 68f7280186056b57559331f9fb405cc8dc7094f6
First added on: Mar 01, 2025